DOCSLIB.ORG

From Gene to Gender - What We’Ve Learned and What We Need to Learn - New Prospects in DSD Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
From Gene to Gender - What We’Ve Learned and What We Need to Learn - New Prospects in DSD Research 3rd International Symposium on Disorders of Sex Development 20 – 22 May 2011 · Universität zu Lübeck Programme & Abstracts From Gene to Gender - What we’ve learned and what we need to learn - New Prospects in DSD Research Sessions on Genetics, Hormones & Action, Morphologic Variation in DSD and Clinical Aspects · Round Table · Poster Session and Oral Sessions 20 – 22 May 2011, Lübeck, Germany 1 Contents Contents...................................................................................................................................1 Welcome Remarks ...................................................................................................................3 About EuroDSD........................................................................................................................4 General Information..................................................................................................................5 Scientific Programme ...............................................................................................................6 Social Programme....................................................................................................................9 Speakers’ List.........................................................................................................................10 Poster Presentation................................................................................................................12 Abstracts Keynote Lectures ...................................................................................................15 Abstracts Oral Presentations..................................................................................................31 Abstracts Poster Presentations ..............................................................................................42 Maps.......................................................................................................................................86 Imprint ....................................................................................................................................90 Sponsors ................................................................................................................................91 SHORT STATURE PORTFOLIO Gezielt zum Erfolg Differenzierte Therapie von Wachstumsstörungen für die GH-Therapie für die IGF-I-Therapie NutropinAq® 10 mg/2 ml (30 I.E.), Injektionslösung. Wirkstoff: Somatropin. Zusammensetzung: Eine Zylinderampulle enthält: 10 mg (30 I.E.) Somatropin (humanes Wachstumshormon) aus mittels rekombinanter DNA-Technologie herge- stellt. Sonstige Bestandteile: Natriumchlorid, Phenol, Polysorbat 20, Natriumcitrat, Wasserfreie Citronensäure, Wasser für Injektionszwecke. Anwendungsgebiete: Langzeitbehandlung von Kindern mit Wachstumsstörungen infolge ungenügender Sekretion von endogenem Wachstumshormon (WH). Langzeitbehandlung von Wachstumsstörungen infolge Turner-Syndroms. Behandlung von präpubertären Kindern mit Wachstumsstörungen infolge chronischer Niereninsuffizienz bis zum Zeitpunkt einer Nieren- transplantation. Substitution von WH bei Erwachsenen, die entweder bereits seit der Kindheit o. seit dem Erwachsenenalter an einem WH-Mangel leiden. Gegenanzeigen: Überempfindlichkeit gegen Somatropin o. einen der sonstigen Bestandteile. Patienten mit geschlossener Epiphyse. Patienten mit aktivem Neoplasma. Die NutropinAq®-Therapie muss abgebrochen werden, falls es Anzeichen für ein Tumorwachstum gibt. Patienten mit akuter, schwerer Erkrankung infolge Komplikationen nach einer Herz- o. Bauch- operation, multiplen Unfallverletzungen. Patienten mit akuter Ateminsuffizienz. Nebenwirkungen: Sehr häufig bei Erwachsenen, häufig bei Kindern: Arthralgie, Myalgie, Ödem, peripheres Ödem. Häufig: Antikörper-Bildung, Hypothyreose, verminderte Glukose- toleranz, Kopfschmerzen, Hypertonie, Reaktionen an der Inj.-stelle, Asthenie. Gelegentlich: Malignom, Neoplasma, Anämie, Hypoglykämie, Hyperphosphatämie, Persönlichkeitsstörung, Somnolenz, Nystagmus, Papillenödem, Diplopie, Schwindel, Tachykardie, Hypertonie, Erbrechen, Bauchschmerzen, Blähungen, Übelkeit, Lipodystrophie, Hautatrophie, exfoliative Dermatitis, Urtikaria, Hirsutismus, Hauthypertrophie, Muskelatrophie, Knochenschmerzen, Karpaltunnelsyndrom, Harninkontinenz, Hämaturie, Polyurie, erhöhte Harnlassfrequenz/Pollakisurie, Urinanomalie, Genitalfluor, an der Inj.-stelle: Atrophie, Blutung u. Schwellung, Hypertrophie. Selten: Diabetes mellitus, Neuropathie, intrakranieller Hochdruck, Diarrhoe, abnorme Nierenfunktionswerte. Häufig: ZNS-Neoplasma. Häufig: Menorrhagie. Häufig: Nierenversagen, Peritonitis, Knochennekrose, erhöhter Kreatininspiegel. Sehr häufig: Parästhesie. Häufig: Hyperglykämie, Hyperlipidämie, Schlaflosigkeit, Störung der Synovialis, Arthrose, Muskelschwäche, Rückenschmerzen, Brustschmerzen, Gynäkomastie. Verstärktes Wachstum von Muttermalen o. Leberflecken möglich. Bei Kindern mit WH-Mangel Risiko für intrakraniellen Hochdruck. Patienten mit endokrin. Störung Risiko für Epiphysiolyse. Leukämie bei einer kleinen Anzahl Patienten mit WH-Mangel. Ursächlich. Zshg. mit Therapie unwahrscheinlich. Die Informationen zu Warnhinweisen und Vorsichtsmaßnahmen sowie Wechselwirkungen mit anderen Mitteln entnehmen Sie bitte der Fachinformation. Verschreibungspflichtig (NR). Ipsen Pharma GmbH, 76275 Ettlingen. Stand der Information: Oktober 2006. Zul.-Nr.: EU/1/00/164/003, EU/1/00/164/005 INCRELEX® 10 mg/ml Injektionslösung. Wirkstoff: Mecasermin. Zusammensetzung: Jeder ml enthält 10 mg Mecasermin. Jede Durchstechflasche enthält 40 mg Mecasermin. Mecasermin ist ein aus Zellen mittels rekombinanter DNA-Technologie ge- wonnener humaner IGF-1. Sonstige Bestandteile: Benzylalkohol, Natriumchlorid, Polysorbat 20, Essigsäure 99 %, Natriumacetat, Wasser für Injektionszwecke. Wirkstoffgruppe: Somatropin und Somatropin-Agonisten. Anwendungsgebiete: Für die Langzeitbehand- lung von Wachstumsstörungen bei Kindern und Jugendlichen mit schwerem primärem Mangel an IGF-1. Schwerer primärer IGF-1-Mangel wird definiert durch: Körpergrößen-SDS≤ -3,0 und basale IGF-1-Konzentration unterhalb der 2,5. Perzentile für Alter und Geschlecht und Wachstumshormonsuffizienz. Ausschluss der sekundären Formen des IGF-1-Mangels wie Unterernährung, Schilddrüsenunterfunktion oder chronische Behandlung mit pharmakologischen Dosen von anti-inflammatorischen Steroiden. Schwerer primärer IGF-1-Mangel umfasst Patienten mit Mutationen im GH-Rezeptor (GHR), mit Mutationen im Post-GHR-Signalweg und mit IGF-1-Gendefekten; sie haben keinen Wachstumshormonmangel, weshalb nicht zu erwarten ist, dass sie auf eine Behandlung mit exogen gegebenem Wachstums- hormon ausreichend ansprechen. Eine Bestätigung der Diagnose durch einen IGF-1-Generationstest wird empfohlen. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. Intravenöse Anwendung. Aktives Neoplasma oder Verdacht auf Neoplasma. Falls es Anzeichen für ein Tumorwachstum gibt, muss die Behandlung abgebrochen werden. Benzylalkohol darf bei Früh- oder Neugeborenen nicht angewendet werden. Nebenwirkungen: Sehr häufig: Thymushypertrophie, Kopfschmerzen, Hypakusis, tonsilläre Hypertrophie, Schnarchen, Hypoglykämie, Hypertrophie an der Injektionsstelle. Häufig: Herzgeräusche, abnormale Tympanometrie, abnormales EKG, erhöhte Alaninaminotransferase*, erhöhte Aspartataminotransferase*, Gewichtszunahme, Kardio- megalie, Ventrikelhypertrophie, atriale Hypertrophie*, Tachykardie, paroxysmale Tachykardie*, Mitralklappeninsuffizienz*, Trikuspidalklappeninsuffizienz*, kongenitale Kieferfehlbildung, Pigmentnävus*, Lymphadenopathie*, Krämpfe, fieberhafte Krämpfe*, benigner intrakranieller Hochdruck, Bewusstlosigkeit*, Schlafapnoe, Schwindel, Zittern*, Restless legs*, Papillenödem, reduzierte Sehleistung*, Myopie*, Otorrhoe, Ohrenerkrankung*, Mittelohrerkrankung*, Trommelfellerkrankung*, Ohrenschmerzen, verstopfte Ohren*, Flüssigkeit im Mittelohr, Hypertrophie der Adenoide, Hypertrophie der Nasenmuschel*, Dyspnoe*, Nasenschleimhauterkrankungen*, obstruktive Atemwegserkrankungen*, abnormale Atmung*, verstopfte Nase, Mundatmung, Erbrechen, Brechreiz*, Bauchschmerzen*, Schmerzen im Oberbauch*, abdominale Distension*, Dysphagie*, Nierensteine*, Hydronephrose*, Nierenkolik*, Hauthypertrophie, Akrochordon*, abnormale Haarstruktur*, Arthralgie, Schmerzen in den Extremitäten, Myalgie, Skoliose*, Wirbelsäulendeformität*, Weichteilerkran- kungen*, Muskelkrämpfe*, Flankenschmerz*, Steifheit des Bewegungsapparats*, hypoglykämischer Anfall, Hyperglykämie, Hyperlipidämie*, Adipositas*, fieberhafte Infektion*, Infektion der oberen Atemwege*, Otitis media, seröse Otitis media, chronisch-seröse Otitis media*, Otitis externa*, Pharyngitis*, Tonsillitis, Ohrenentzündung, Mundsoor*, Adenotonsillektomie*, Adenoidektomie, Einsetzen von Ohrröhrchen, Schleimhauthyperplasie, Hypertrophie, Schmerzen an der Injektionsstelle, Bluterguss an der Injektionsstelle, Fibrose an der Injektionsstelle*, Reaktion an der Injektionsstelle*, Schwellung an der Injektionsstelle*, Verhärtung an der Injektionsstelle*, Pigmentveränderung an der Injektionsstelle*, Schleimhautödem*, Asthenie*, Lethargie*, Beschwerden in der Brust*, Gynäkomastie, Eierstock- zyste*, Depression*, Nachtangst, Nervosität, abnormales Verhalten*, Verwirrung* (* = trat bei nur 1 Patienten (1 %) auf). Die nachfolgenden Nebenwirkungen wurden nach Markteinführung von INCRELEX beobachtet. Da diese Nebenwirkungen auf freiwilliger Basis aus einer
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Webbed Penis
    Kathmandu University Medical Journal (2010), Vol. 8, No. 1, Issue 29, 95-96 Case Note Webbed penis: A rare case Agrawal R1, Chaurasia D2, Jain M3 1Resident in Surgery, 2Associate Professor, Department of Urology, 3Assistant Professor, Department of Plastic and Reconstructive Surgery, MLN Medical College, Allahabad (India) Abstract Webbed penis belongs to a rare and little-known defect of the external genitalia. The term denotes the penis of normal size for age hidden in the adjacent scrotal and pubic tissues. Though rare, it can be treated easily by surgery. A case of webbed penis is presented with brief review of literature. Key words: penis, webbed ebbed penis is a rare anomaly of structure of Wpenis. Though a congenital anomaly, usually the patient presents in late childhood or adolescence. Skin of penis forms the shape of a web, covering whole or part of penis circumferentially; with or without glans, burying the penile tissue inside. The length of shaft is normal with normal stretched length. Phimosis may be present. The penis appears small without any diffi culty in voiding function. Fig 1: Penis showing web Fig 2: Markings for double of skin on anterior Z-plasty on penis Case report aspect Our patient, a 17 year old male, presented to us with congenital webbed penis. On examination, skin webs Discussion were present on both lateral sides from prepuce to lateral Webbed penis is a developmental malformation with aspect of penis.[Fig. 1] On ventral aspect, the skin web less than 60 cases reported in literature. The term was present from prepuce to inferior margin of median denotes the penis of normal size for age hidden in the raphe of scrotum.
    [Show full text]
  • Müllerian Aplasia and Hyperandrogenism
    Müllerian aplasia and hyperandrogenism Description Müllerian aplasia and hyperandrogenism is a condition that affects the reproductive system in females. This condition is caused by abnormal development of the Müllerian ducts, which are structures in the embryo that develop into the uterus, fallopian tubes, cervix, and the upper part of the vagina. Individuals with Müllerian aplasia and hyperandrogenism typically have an underdeveloped or absent uterus and may also have abnormalities of other reproductive organs. Women with this condition have normal female external genitalia, and they develop breasts and pubic hair normally at puberty; however, they do not begin menstruation by age 16 (primary amenorrhea) and will likely never have a menstrual period. Affected women are unable to have children ( infertile). Women with Müllerian aplasia and hyperandrogenism have higher-than-normal levels of male sex hormones called androgens in their blood (hyperandrogenism), which can cause acne and excessive facial hair (facial hirsutism). Kidney abnormalities may be present in some affected individuals. Frequency Müllerian aplasia and hyperandrogenism is a very rare disorder; it has been identified in only a few individuals worldwide. Causes Mutations in the WNT4 gene cause Müllerian aplasia and hyperandrogenism. This gene belongs to a family of WNT genes that play critical roles in development before birth. The WNT4 gene provides instructions for producing a protein that is important for the formation of the female reproductive system, the kidneys, and several hormone- producing glands. During the development of the female reproductive system, the WNT4 protein regulates the formation of the Müllerian ducts. This protein is also involved in development of the ovaries, from before birth through adulthood, and is important for development and maintenance of egg cells (oocytes) in the ovaries.
    [Show full text]
  • Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation Nicole Bowles
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2013 Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation Nicole Bowles Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Bowles, Nicole, "Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation" (2013). Student Theses and Dissertations. Paper 232. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. CANNABINOID CB1R RECEPTOR MEDIATES METABOLIC SYNDROME IN MODELS OF CIRCADIAN AND GLUCOCORTICOID DYSREGULATION A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Nicole Bowles June 2013 Copyright by Nicole Bowles 2013 CANNABINOID CB1R RECEPTOR MEDIATES METABOLIC SYNDROME IN MODELS OF CIRCADIAN AND GLUCOCORTICOID DYSREGULATION Nicole Bowles, Ph.D. The Rockefeller University 2013 The most recent projections in the growing obesity rates across the nation show an increase to 60% by the year 2030. These growing rates of obesity are paralleled by an increased rates of depressive conditions, anxiety, and sleep loss, often with environmental factors at the root of the cause. Stress and the stress response is a dynamic system that reflects one’s ability to cope with events, behaviorally or physiologically, as stressors occur over a lifetime. While many key players mediate the effects of stress exposure on disease outcomes including the sympathetic nervous system, parasympathetic, inflammatory cytokines and metabolic hormones, this dissertation focuses on glucocorticoids because of the extensive regulatory role they play in mounting the adaptative response to stress.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Guidelines on Paediatric Urology S
    Guidelines on Paediatric Urology S. Tekgül (Chair), H.S. Dogan, E. Erdem (Guidelines Associate), P. Hoebeke, R. Ko˘cvara, J.M. Nijman (Vice-chair), C. Radmayr, M.S. Silay (Guidelines Associate), R. Stein, S. Undre (Guidelines Associate) European Society for Paediatric Urology © European Association of Urology 2015 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Aim 7 1.2 Publication history 7 2. METHODS 8 3. THE GUIDELINE 8 3A PHIMOSIS 8 3A.1 Epidemiology, aetiology and pathophysiology 8 3A.2 Classification systems 8 3A.3 Diagnostic evaluation 8 3A.4 Disease management 8 3A.5 Follow-up 9 3A.6 Conclusions and recommendations on phimosis 9 3B CRYPTORCHIDISM 9 3B.1 Epidemiology, aetiology and pathophysiology 9 3B.2 Classification systems 9 3B.3 Diagnostic evaluation 10 3B.4 Disease management 10 3B.4.1 Medical therapy 10 3B.4.2 Surgery 10 3B.5 Follow-up 11 3B.6 Recommendations for cryptorchidism 11 3C HYDROCELE 12 3C.1 Epidemiology, aetiology and pathophysiology 12 3C.2 Diagnostic evaluation 12 3C.3 Disease management 12 3C.4 Recommendations for the management of hydrocele 12 3D ACUTE SCROTUM IN CHILDREN 13 3D.1 Epidemiology, aetiology and pathophysiology 13 3D.2 Diagnostic evaluation 13 3D.3 Disease management 14 3D.3.1 Epididymitis 14 3D.3.2 Testicular torsion 14 3D.3.3 Surgical treatment 14 3D.4 Follow-up 14 3D.4.1 Fertility 14 3D.4.2 Subfertility 14 3D.4.3 Androgen levels 15 3D.4.4 Testicular cancer 15 3D.5 Recommendations for the treatment of acute scrotum in children 15 3E HYPOSPADIAS 15 3E.1 Epidemiology, aetiology and pathophysiology
    [Show full text]
  • Guidelines on Paediatric Urology S
    Guidelines on Paediatric Urology S. Tekgül, H. Riedmiller, E. Gerharz, P. Hoebeke, R. Kocvara, R. Nijman, Chr. Radmayr, R. Stein European Society for Paediatric Urology © European Association of Urology 2011 TABLE OF CONTENTS PAGE 1. INTRODUCTION 6 1.1 Reference 6 2. PHIMOSIS 6 2.1 Background 6 2.2 Diagnosis 6 2.3 Treatment 7 2.4 References 7 3. CRYPTORCHIDISM 8 3.1 Background 8 3.2 Diagnosis 8 3.3 Treatment 9 3.3.1 Medical therapy 9 3.3.2 Surgery 9 3.4 Prognosis 9 3.5 Recommendations for crytorchidism 10 3.6 References 10 4. HYDROCELE 11 4.1 Background 11 4.2 Diagnosis 11 4.3 Treatment 11 4.4 References 11 5. ACUTE SCROTUM IN CHILDREN 12 5.1 Background 12 5.2 Diagnosis 12 5.3 Treatment 13 5.3.1 Epididymitis 13 5.3.2 Testicular torsion 13 5.3.3 Surgical treatment 13 5.4 Prognosis 13 5.4.1 Fertility 13 5.4.2 Subfertility 13 5.4.3 Androgen levels 14 5.4.4 Testicular cancer 14 5.4.5 Nitric oxide 14 5.5 Perinatal torsion 14 5.6 References 14 6. Hypospadias 17 6.1 Background 17 6.1.1 Risk factors 17 6.2 Diagnosis 18 6.3 Treatment 18 6.3.1 Age at surgery 18 6.3.2 Penile curvature 18 6.3.3 Preservation of the well-vascularised urethral plate 19 6.3.4 Re-do hypospadias repairs 19 6.3.5 Urethral reconstruction 20 6.3.6 Urine drainage and wound dressing 20 6.3.7 Outcome 20 6.4 References 21 7.
    [Show full text]
  • Study the Levels of Adiponectin, FSH, LH and Sex Hormones In
    Journal of Biology, Agriculture and Healthcare www.iiste.org ISSN 2224-3208 (Paper) ISSN 2225-093X (Online) Vol.3, No.2, 2013 Study the levels of adiponectin, FSH, LH and Sex hormones in Type 2 diabetes (NIDDM) Tahrear Mohammed Natah 1* , Moshtak Abdul- Adheem Wtwt 2, Haider Kamil Al-Saadi 3, Ali Hmood Al-Saadi 4, Hadeel Fadhil Farhood 5 1, 3, 4. Biology Department, College of Science, Babylon University, Iraq. 3,5. Biology Department, Medicine College, Babylon University, Iraq. * E-mail: [email protected] Abstract The hypothalamic/pituitary/gonadal (HPG)axis is central to the mammalian reproductive system . Pulsatile release of GnRH from neurons in the hypothalamus stimulates the secretion of LH and FSH from gonadotropes in the anterior pituitary. It has long been recognized that reproductive function is closely associated with energy balance, and metabolic dysregulation is linked with reproductive abnormalities (Lu et al .,2008). Compare the differences in levels of adiponectin, FSH, LH, testosterone and estradiol between the diabetic patients and control group and in diabetic patients according to the durations of disease for both males and females groups .Also study the relationship between adiponectin and hormones for both gender and for both diabetic groups and control also in diabetic patients according to the durations of disease. About five milliliters of venous blood were collected from each subject in the study. The blood was separated by centrifugation at (3000 rpm) for 15 min. The sera were stored frozen at (-20 ºC) until
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Level Estimates of Maternal Smoking and Nicotine Replacement Therapy During Pregnancy
    Using primary care data to assess population- level estimates of maternal smoking and nicotine replacement therapy during pregnancy Nafeesa Nooruddin Dhalwani BSc MSc Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2014 ABSTRACT Background: Smoking in pregnancy is the most significant preventable cause of poor health outcomes for women and their babies and, therefore, is a major public health concern. In the UK there is a wide range of interventions and support for pregnant women who want to quit. One of these is nicotine replacement therapy (NRT) which has been widely available for retail purchase and prescribing to pregnant women since 2005. However, measures of NRT prescribing in pregnant women are scarce. These measures are vital to assess its usefulness in smoking cessation during pregnancy at a population level. Furthermore, evidence of NRT safety in pregnancy for the mother and child’s health so far is nebulous, with existing studies being small or using retrospectively reported exposures. Aims and Objectives: The main aim of this work was to assess population- level estimates of maternal smoking and NRT prescribing in pregnancy and the safety of NRT for both the mother and the child in the UK. Currently, the only population-level data on UK maternal smoking are from repeated cross-sectional surveys or routinely collected maternity data during pregnancy or at delivery. These obtain information at one point in time, and there are no population-level data on NRT use available. As a novel approach, therefore, this thesis used the routinely collected primary care data that are currently available for approximately 6% of the UK population and provide longitudinal/prospectively recorded information throughout pregnancy.
    [Show full text]
  • Genetic Disorders in Premature Ovarian Failure
    Human Reproduction Update, Vol.8, No.4 pp. 483±491, 2002 Genetic disorders in premature ovarian failure T.Laml1,3, O.Preyer1, W.Umek1, M.HengstschlaÈger2 and E.Hanzal1 University of Vienna Medical School, Department of Obstetrics and Gynaecology, 1Division of Gynaecology and 2Division of Prenatal Diagnosis and Therapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria 3To whom correspondence should be addressed. E-mail: [email protected] This review presents the genetic disorders associated with premature ovarian failure (POF), obtained by Medline, the Cochrane Library and hand searches of pertinent references of English literature on POF and genetic determinants cited between the year 1966 and February 2002. X monosomy or X deletions and translocations are known to be responsible for POF. Turner's syndrome, as a phenotype associated with complete or partial monosomy X, is linked to ovarian failure. Among heterozygous carriers of the fragile X mutation, POF was noted as an unexpected phenotype in the early 1990s. Autosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identi®ed in patients with POF. In conclusion, the relationship between genetic disorders and POF is clearly demonstrated in this review. Therefore, in the case of families affected by POF a thorough screening, including cytogenetic analysis, should be performed. Key words: autosomal disorders/FSH receptor/inhibin/premature ovarian failure/X chromosome abnormalities TABLE OF CONTENTS diagnosis requires histological examination of a full-thickness ovarian biopsy (Metha et al., 1992; Olivar, 1996).
    [Show full text]